Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com
About REXAHN
Rexahn is developing novel drugs for cancer and CNS disorders. Our differentiated product pipline to day features several potential first-in-class therapies in CNS and Cancer.